Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

View Full Paper
Ask AI
Bookmark
Share

Authors

CRCédric RossiFJFabrice JardinGDGandhi Damaj

Discussion

Loading...

Member takes

Overview

Retrospective cohort study shows improved event-free survival for axi-cel over standard therapy in relapsed large B cell lymphoma, suggesting potential benefits.

Key Points

  • Event-free survival at one year was significantly better for axi-cel at 46% compared to 16% for standard regimens, indicating noticeable effectiveness.
  • Kaplan–Meier estimator was employed to assess time-to-event outcomes across 356 axi-cel and 132 SOC patients.
  • Analysis included propensity scores to balance baseline characteristics among early relapsed large B cell lymphoma patients receiving different therapies.
  • Highlights the need for further studies to evaluate the long-term impact of CAR T-cell therapy in large B cell lymphoma.

Cite This Study

Rossi et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db88https://doi.org/10.1182/blood-2025-2764
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study2025
  2. 2Real-world evaluation of health care resource utilization, clinical effectiveness, and safety of lisocabtagene maraleucel and axicabtagene ciloleucel administered in the outpatient (OP) setting for R/R large B-cell lymphoma (LBCL)2025
  3. 3Real-world analysis of axicabtagene ciloleucel (axi-cel) as consolidation therapy following first-line treatment in B-cell lymphoma with high-risk factors2025
  4. 4Axi-cel delivers similar outcomes regardless of ASCT-eligibility in second line R/R LBCL: Combined data from ZUMA-7 and ALYCANTE2025 · 2 citations
  5. 5Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma2025 · 21 citations